5,026.00
-88.00 (-1.72%)
as of 2026-08-17 · marketstack
quoted in pence (GBX)
stale — last close 2026-08-17, not a live quote
Clinical trials
catalyst calendar across sponsors →Studies where RKT.L is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
19 interventional · 17 with posted results
government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of Mucinex™(Guaifenesin) 600 mg Extended-Release Bi-Layer Tablets in the Treatment of Otherwise Healthy Patients With Symptoms of Cough, Thickened Mucus and Chest CongestionNCT03725085results2019-03-19Number of Adverse Events (AEs), Type of AE(s) and Frequency of AE(s)Open-label · Basic science | Phase 4 | Completed | Drug: Mucinex™ extended-release (SE) | Healthy Subjects | 552 | 2015-10-16actual | 2019-03-19 |
| Placebo-Controlled Onset-of-Action Study of Flurbiprofen Utilizing the Double-Stopwatch MethodNCT01986361results2017-08-24Kaplan-Meier Estimates for Time to Meaningful Pain ReliefRandomized · Double-masked · Treatment | Phase 3 | Completed | Drug: flurbiprofen, placebo | Acute Pharyngitis, Sore Throat | 122 | Apr 2014actual | 2017-09-28 |
| Mucinex® ER 600 mg Bi-layer Tablet Versus Guaifenesin Immediate Release (IR) 200 mg q4hNCT03642262results2019-06-17Maximum Observed Plasma Concentration (Cmax) of GuaifenesinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Mucinex® | Healthy Subjects | 30 | 2013-08-09actual | 2019-06-17 |
| Mucinex® ER 600 mg Bi-Layer Tablet Fed and FastedNCT03649750results2019-02-22Maximum Observed Plasma Concentration (Cmax) of GuaifenesinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Mucinex® | Healthy Subjects | 36 | 2013-08-07actual | 2019-03-27 |
| Safety & Performance Study of Verruca Treatment DeviceNCT01536834Safety EndpointOpen-label · Treatment | Not applicable | Completed | Device: Medical Device | Verruca, Plantar Wart | 35 | Jan 2013actual | 2017-10-11 |
| Evaluation of Tolerance and Acceptability of a Coated CondomNCT01619397To demonstrate dermatological tolerance.Open-label · Other | Not applicable | Completed | Device: Test condom with new Xanthan gum condom coating | Tolerance and Acceptability of a New Condom Coating | 50 | Oct 2012actual | 2017-09-11 |
| Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract InfectionsNCT01537081results2013-09-12Summary Scores on the SUM8 Daily Cough and Phlegm Diary Card On the Morning of Day 4Randomized · Double-masked · Treatment | Phase 2/3 | Completed | Drug: Mucinex, Immediate-release Guaifenesin, Placebo | Acute Upper Respiratory Tract Infection | 2,810 | Mar 2012actual | 2013-11-14 |
| Study to Evaluate the Pharmacokinetics of Mucinex® 1200 mg Extended-Release TabletNCT03633487results2019-02-28Maximum Observed Plasma Concentration (Cmax)Open-label · Basic science | Phase 1 | Completed | Drug: Mucinex® | Healthy Subjects | 24 | 2011-10-15actual | 2019-02-28 |
| Study to Evaluate the Pharmacokinetics of Guaifenesin in Adults and AdolescentsNCT03633448results2019-06-17Area Under Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration (AUC(0-t)) of GuaifenesinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Children's Mucinex® Grape Flavor, Children's Mucinex® Grape Flavor | Healthy Subjects | 24 | 2011-07-01actual | 2019-06-17 |
| Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory InfectionNCT01114581results2012-10-08Percent of Inhaled Radioactive Tracer Particles Cleared From LungsRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Mucinex, Placebo | Acute Respiratory Infection | 38 | Apr 2011actual | 2018-09-19 |
| A Study of Flurbiprofen 8.75 mg Lozenge in Patients With PharyngitisNCT01048866results2017-09-21Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: placebo, flurbiprofen, acetaminophen 650mg | Pharyngitis | 198 | Mar 2011actual | 2017-09-21 |
| A Study of Flurbiprofen 8.75 mg Lozenge in Patient With PharyngitisNCT01049334results2017-09-21Time Weighted Sum of Pain Intensity Differences (SPID) in Sore Throat Pain Intensity Scale (STPIS) Over the 24 Hours Post-baseline (STPIS SPID24)Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Flurbiprofen | Pharyngitis | 204 | Mar 2011actual | 2017-09-21 |
| Safety and Efficacy Study of Guaifenesin and Pseudoephedrine for Symptomatic Therapy to Treat Acute RTINCT01202279results2012-11-05Antibiotic SparingRandomized · Quadruple-masked · Prevention | Phase 4 | Completed | Drug: Guaifenesin · Device: Placebo | Acute Upper Respiratory Track Infection | 1,179 | Apr 2010actual | 2020-12-30 |
| Mucinex Exploratory Cold StudyNCT01046136results2012-08-24Investigator's End of Study Assessment of TreatmentRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: guaifenesin (Mucinex), placebo | Common Cold | 378 | Mar 2010actual | 2020-12-30 |
| Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain StudyNCT01229449results2018-09-17Change From Baseline in Area Under the Curve (AUC) of Pain Intensity and Relief Scores (SPRID)Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Ibuprofen/acetaminophen, Ibuprofen/acetaminophen (higher dose), Nurofen Plus®, Panadeine® Extra, Placebo | Post-operative Pain | 678 | Sep 2009actual | 2018-09-17 |
| Study to Characterize the Pharmacokinetics of 3 Marketed Products Containing 200 mg Guaifenesin in Healthy Volunteers.NCT03643575results2019-02-22Maximum Observed Plasma Concentration (Cmax) of GuaifenesinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Vicks Cough Syrup for Chesty Coughs, Robitussin Extra Strength Chest Congestion, Organ-I- NR tablet | Healthy Subjects | 30 | 2009-07-16actual | 2019-03-27 |
| Study to Evaluate the Pharmacokinetics of Mucinex 600 mg Extended-release Bi-layer Tablet in Healthy VolunteersNCT03644108results2019-02-28Maximum Observed Plasma Concentration (Cmax) of GuaifenesinOpen-label · Basic science | Phase 1 | Completed | Drug: Mucinex® ER 600 mg | Healthy Subjects | 30 | 2009-06-15actual | 2019-02-28 |
| Bioequivalence Study Comparing Mucinex Extended-release 600 mg Tablets to Immediate-release Guaifenesin 600 mg in Healthy VolunteersNCT03644095results2019-06-19Maximum Observed Plasma Concentration (Cmax) of GuaifenesinRandomized · Open-label · Basic science | Phase 1 | Completed | Drug: Mucinex® SE, Vicks Cough Syrup for Chesty Coughs | Healthy Subjects | 30 | 2009-02-01actual | 2019-06-19 |
| Study to Evaluate Drug-drug Interactions of Guaifenesin and Hydrocodone BitartrateNCT03642873results2019-06-20Maximum Observed Plasma Concentration (Cmax) of GuaifenesinRandomized · Open-label · Supportive care | Phase 1 | Completed | Drug: Humibid®, Hydrocodone Bitartrate, Humibid® and Hydrocodone Bitartrate tablet | Healthy Subjects | 24 | 2007-05-21actual | 2019-06-20 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19